52186-05-7 Usage
Structure
Cyclic ketone with two benzyl groups
2,5-Dibenzylcyclopentanone has a five-membered carbon ring (cyclopentanone) with two phenyl groups (benzyl) attached to it.
Usage in organic chemistry and chemical research
Starting material for synthesis
This compound is commonly used as a starting material for the synthesis of other chemical compounds in organic chemistry and chemical research.
Potential pharmacological uses
Anti-inflammatory and anti-cancer properties
Research has suggested that 2,5-Dibenzylcyclopentanone may have potential pharmacological applications, such as anti-inflammatory and anti-cancer effects.
5. Potential application in new materials development
2,5-Dibenzylcyclopentanone has been studied for its possible use in the development of new materials due to its unique chemical structure and properties.
6. Use as a reagent in various chemical reactions
The compound is also used as a reagent in a variety of chemical reactions, further expanding its applications in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 52186-05-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,1,8 and 6 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 52186-05:
(7*5)+(6*2)+(5*1)+(4*8)+(3*6)+(2*0)+(1*5)=107
107 % 10 = 7
So 52186-05-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H22O/c1-15(13-17-9-5-3-6-10-17)19(20)16(2)14-18-11-7-4-8-12-18/h3-12,15-16H,13-14H2,1-2H3
52186-05-7Relevant articles and documents
New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3
Stefane, Bogdan,Brozic, Petra,Vehovc, Matej,Rizner, Tea Lanisnik,Gobec, Stanislav
experimental part, p. 2563 - 2571 (2009/10/17)
A series of cyclopentane derivatives was synthesized and evaluated for inhibition of the steroid metabolizing enzymes AKR1C1 and AKR1C3. Selective inhibitors that are active in the low micromolar range were identified. These compounds represent promising starting points in the development of new anticancer agents for the treatment of hormone-dependent forms of cancer and other diseases where AKR1C1 and AKR1C3 are involved.
